Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Daily Subcutaneous Injections of Elamipretide in Subjects With Primary Mitochondrial Disease Resulting From Pathogenic Nuclear DNA Mutations (nPMD) - NuPower Study

Next Previous
Trial Profile

A Phase 3 Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Daily Subcutaneous Injections of Elamipretide in Subjects With Primary Mitochondrial Disease Resulting From Pathogenic Nuclear DNA Mutations (nPMD) - NuPower Study

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 17 Jul 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Elamipretide (Primary)
  • Indications Mitochondrial myopathies
  • Focus Registrational; Therapeutic Use
  • Acronyms NuPOWER
  • Sponsors Mighty Therapeutics; Stealth BioTherapeutics

Most Recent Events

  • 16 Jun 2026 According to Stealth BioTherapeutics media release, Stealth BioTherapeutics is now called Mighty Therapeutics.
  • 26 May 2026 According to a Stealth BioTherapeutics media release, data from this trial will be presented at the International Meeting on Mitochondrial Pathology (Euromit), which is being held May 31-June 4, 2026, in Angers, France.
  • 29 Jul 2024 According to a Stealth BioTherapeutics media release, Elamipretide is in Phase 3 development for primary mitochondrial myopathy, with pivotal data expected in late 2024

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top